ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 962

A Systematic Review and Network Meta-Analysis of the Risk of Serious Infections with Immunosuppressives for Lupus Nephritis

Jasvinder A. Singh1, Alomgir Hossain2, Ahmed Kotb2 and George Wells3, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Ottawa, Ottawa, ON, Canada, 3Cardiovascular Resarch Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Lupus nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Lupus Nephritis

Session Type: Abstract Submissions (ACR)

Background/Purpose

To compare the risk of serious infections of immunosuppressive medications used for the treatment of lupus nephritis.

Methods

We performed an up to date systematic review and network meta-analysis  (NMA) by performing an updated search for randomized trails of immunosuppressive medications for lupus nephritis up to September 2013 with the help of Cochrane and ACR librarians. We updated the data from the systematic review for the 2012 ACR lupus nephritis treatment recommendations and the published Cochrane Review on lupus nephritis. We abstracted data related to infections from these trials. Bayesian network meta-analyses (NMA) were conducted. A binomial likelihood model, which allows for the use of multi-arm trials was used. Informed priors were assigned for basic parameters and odds ratios, as well as risk ratios and risk differences, and 95% credible intervals were modeled using Markov chain Monte Carlo methods. Brooks-Gelman-Rubin plots were used to assess model convergence. Model fit was examined using the deviance information criterion (DIC) and the residual deviance. The degree of inconsistency was assessed by comparing statistics for the deviance and deviance information criterion in fitted consistency and inconsistency models. In further sensitivity analyses, fixed effects models and models using vague priors were also conducted.

Results

31 RCTs with 2, 442 patients provided data.  There were twenty-five 2-arm, five 3-arm and one 4-arm trial. We found that tacrolimus was associated with significantly lower risk of serious infections compared to prednisone, cyclophosphamide, mycophenolate mofetil and azathioprine with a risk approximately one-third  (Table 1).  We also found that MMF-AZA (MMF followed by AZA) was associated with significantly lower risk of serious infections as compared to low dose CYC, high dose CYC or high dose prednisone, although this was based on fewer data (Table 1).  Other differences between immunosuppressives did not reach statistical significance. 

Conclusion

Tacrolimus and MMF-AZA combination were associated with lower risk of serious infections  serious infections compared to other treatment options for lupus nephritis. These numbers can help patients make informed decisions about treatment options for lupus nephritis. 

 

Table 1. Comparison of various drugs for the risk of infections in patients with lupus nephritis showing statistically significant results

Treatment

Reference

Odds Ratio    

(95% Credible Interval [CrI])

Relative Risk     (95% CrI)

Risk Difference %   (95% Crl)

TAC

PRED

0.30 (0.10,0.86)

0.34 (0.11, 0.88)

-8.97 (-15.82, -1.46)

TAC

CYC

0.34 (0.13,0.87)

0.38 (0.14, 0.88)

-7.47 (-13.89, -1.26)

TAC

MMF

0.35 (0.14,0.82)

0.38 (0.16, 0.84)

-7.23 (-15.34, -1.53)

TAC

AZA

0.28 (0.09,0.81)

0.32 (0.11, 0.83)

-9.61 (-20.74, -1.73)

MMF-AZA

CYC LD

0.09 (0.01,0.80)

0.12 (0.01, 0.83)

-17.42 (-42.84, -2.08)

MMF-AZA

PRED HD

0.03 (0.00,0.59)

0.06 (0.01, 0.64)

-37.87 (-82.60, -3.54)

MMF-AZA

CYC HD

0.07 (0.01,0.56)

0.09 (0.01, 0.62)

-22.74 (-46.47, -6.14)


Disclosure:

J. A. Singh,

Savient,

2,

Takeda,

2,

Degeneron,

5,

Allergan ,

5;

A. Hossain,
None;

A. Kotb,
None;

G. Wells,

Novartis, Bristol- Myers Squibb, and Abbott,

5,

Bristol-Myers Squibb,

2,

Abbott Immunology Pharmaceuticals,

8,

he is a member of the executive of OMERACT and of the Scientific Committee for the Ontario Biologics Research Initiative,

9.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-systematic-review-and-network-meta-analysis-of-the-risk-of-serious-infections-with-immunosuppressives-for-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology